Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
(A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH agonist
 (Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density in the
 two treated groups in order to demonstrate that NA does not affect bone density; (B) Minor:
 1) To compare the lipid profiles of patients in the two groups to confirm the hypothesis that
 the effects of NA and GnRH agonists on lipid profiles are similar, 2) To determine whether
 quality of life, assessed by questionnaire, is better in patients assigned to NA than in
 patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects than GnRH
 agonist.
Objectives: (A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH
 agonist (Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density
 in the two treated groups in order to demonstrate that NA does not affect bone density; (B)
 Minor: 1) To compare the lipid profiles of patients in the two groups to confirm the
 hypothesis that the effects of NA and GnRH agonists on lipid profiles are similar, 2) To
 determine whether quality of life, assessed by questionnaire, is better in patients assigned
 to NA than in patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects
 than GnRH agonist.

 After signing an IRB approved consent from 112 women with symptomatic endometriosis,
 diagnosed surgically, will be treated with NA or Lupron-Depot-3 for 24 weeks. After 24 weeks
 both groups will be treated only with NA until 52 weeks. After that, both groups will be
 followed for an additional 52 weeks to assess any return of clinical symptoms and to
 determine whether laboratory tests of drug related changes return to pretreatment levels.

 Treatment regimens are as follows: For the first 24 weeks, women in the NA group will be
 treated with 5 mg NA daily and a placebo injection every 12 weeks. In case of bleeding, the
 NA dose will be increased (max 15 mg) until bleeding stops, and then decreased by 2.5 mg
 every 4 weeks to a final dose of 7.5 mg which will be maintained for the remainder of the 24
 weeks. For the first 24 weeks, women in the GnRH groups will receive Lupron-Depot-3
 injections every 12 weeks plus placebo pills daily - bleeding will be treated with an
 increase in placebo pills to simulate treatment in the NA group. After 24 weeks, all women
 will be on identical regimens of 5 mg NA pills daily and no injections.

 On the first treatment day, subjects will have the following tests/assessments: bone density
 with DEXA, scoring of endometriosis symptoms, quality of life questionnaire, general physical
 examination, lipid profile, estradiol (E2), N-telopeptide, and pregnancy test. All tests,
 except bone density and lipid profile, will be repeated at 12, 24, and 52 weeks of treatment.
 Bone density will be performed at 24 and 52 weeks and lipid profile will be performed at 12
 and 52 weeks of treatment. In the follow-up period, physical examination, quality of life
 questionnaires, scoring of symptoms will be done at 3, 6, 9 and 12 months. Lipid profile,
 N-telopeptide and E2 will be performed at 3 and 12 months and bone density at 12 month
 follow-up.

 The objectives stated above will be compared between the two groups at 12, 24, and 52 weeks
 of treatment and at 6-month intervals during the follow-up period.
Inclusion Criteria:

 -  The subject has voluntarily signed the Informed Consent form after having the contents
 fully explained, after all questions are answered and prior to undergoing any
 study-related procedures.

 -  The subject is a pre-menopausal female at least 18 years of age at the time of
 screening having regular periods (21-42 days intervals) with no menopausal symptoms.

 -  The subject has a diagnosis of endometriosis made via laparoscopy or laparotomy
 (operative report will be obtained) and still symptomatic and at least 3 months after
 surgery have a grade 2 and above according to Biberoglu's pain grade at screening
 visit (4 weeks prior initiation of treatment) or 4 out of 10 on a visual pain scale
 (visual analogue)

 -  Subject in good health, except for endometriosis, or has mild medical conditions that
 are stable and controlled. The subject has no clinically relevant hepatic, renal,
 cardiovascular, respiratory, endocrine, metabolic, psychiatric, neurologic (epilepsy),
 hematolytic (coagulopathy) and/or immunologic disease (on steroids) or disorder.

 -  A subject who has received any of the hormone therapies (GnRH agonist or danazol or
 progestin) must meet the minimum washout requirement to be eligible. (GnRH within the
 last 6 months and with steroids within the last month.) After hormonal therapy has
 stopped, the subject must have returned to normal for at least two menstrual cycles
 before baseline time.

 -  Serum pregnancy and urine qualitative pregnancy tests performed at screening and on
 baseline must be negative.

 -  Unless surgical sterile by bilateral tubal ligation or vasectomy of partner, the
 subject agrees to use a double-barrier method of contraception during the screening
 period, throughout the 24-week treatment period, such as: condom plus spermicide,
 diaphragm plus spermicide, sponge plus spermicide, abstinence is an acceptable form of
 birth control.

 -  Less than grade III overweight or BMI <40 kg/M2

 Exclusion Criteria:

 -  Less than 3 months postpartum and post-lactation at the time of dosing.

 -  Abnormal laboratory findings considered clinically significant if more than twice the
 normal range. Abnormal tests will be repeated, and if still high as stated before,
 subject will be excluded.

 -  A previous history of significant adverse reactions to hormone, progestin or
 progesterone and GnRH agonist therapies.

 -  Abnormal Pap smear in the last 6 months. Subjects with ASCUS (atypical squamous cells
 of undetermined significance) and are negative for high-risk human papilloma virus
 (HPV) will be eligible. Subjects that have atypical endocervical cells, and atypical
 glandular cells are not eligible for this study.

 -  Subject has a bone density T score less or equal to 2.5, history of nontraumatic
 fracture, history of spinal surgery, history of fusion of lumbar region, history of
 severe scoliosis greater than 20 degrees.